ライフサイエンスコーパス: primary prevention

1 risk but have not yet had a vascular event (primary prevention).

2 iate therapies, including those implanted in primary prevention.

3 on-making between clinicians and patients in primary prevention.

4 icians to support prescription of aspirin in primary prevention.

5 implantable cardioverter defibrillators for primary prevention.

6 early adulthood to inform discussions about primary prevention.

7 Prophylactic HPV vaccine is available for primary prevention.

8 ear-old man considering starting aspirin for primary prevention.

9 ate other mechanism(s) and the potential for primary prevention.

10 randomized to egg were not amenable to this primary prevention.

11 ealth score (ICHS) is recommended for use in primary prevention.

12 recommendations for using statin therapy in primary prevention.

13 tions to inform the allocation of aspirin in primary prevention.

14 evidence supporting these recommendations in primary prevention.

15 essential in developing strategies aimed at primary prevention.

16 nalyses among patients receiving statins for primary prevention.

17 han offering only community mobilization and primary prevention.

18 in-related risks and benefits is critical in primary prevention.

19 and stroke, and is a decision-making aid for primary prevention.

20 , suggesting adiposity could be targeted for primary prevention.

21 personalized, safer allocation of aspirin in primary prevention.

22 ommendations and management patterns for CAD primary prevention.

23 ent social conditions" anticipated models of primary prevention.

24 ordially, and in individuals at high risk by primary prevention.

25 on-making between clinicians and patients in primary prevention.

26 sed approach to risk factor modification and primary prevention.

27 e conflicting recommendations for its use in primary prevention.

28 In primary prevention, a clinician-patient risk discussion

29 would qualify for aspirin consideration for primary prevention according to the American College of

30 The need to scale-up the primary prevention actions is urgent.

31 f stroke and all-cause mortality in both the primary prevention (adjusted hazard ratio [aHR] for stro

32 TER [Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Ros

33 The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Ros

34 are possible from sufficient uptake of both primary prevention and ART, but with continuation of the

35 Effective strategies are needed for primary prevention and management of carotid atheroscler

36 damage, with the ultimate goal of improving primary prevention and reducing the health care and soci

37 They may also have roles in primary prevention and renal protection.

38 Primary prevention and screening among children and adol

39 ey suggest novel pharmacological methods for primary prevention and treatment of posttraumatic stress

40 abolish reductions in function with ageing (primary prevention) and/or improve function or slow furt

41 ntion strategies that include biomedical and primary prevention approaches add complexity to the task

42 gent need to identify novel risk factors and primary prevention approaches for CVD in HIV.

43 ions include secondary prevention, high-risk primary prevention based on formal risk assessment, and

44 vention based on formal risk assessment, and primary prevention based on single risk factor measureme

45 underwent first-time device implantation for primary prevention between April 2006 and December 2009.

46 o had previously undergone ICD placement for primary prevention but subsequently never received appro

47 diabetes mellitus patients is used to guide primary prevention, but the performance of risk estimato

48 ium (CAC) for guiding aspirin allocation for primary prevention by using 2019 aspirin meta-analysis d

49 ted with cause-specific cardiac mortality in primary-prevention candidates with ischemic cardiomyopat

50 The primary prevention cohort comprised individuals >/=50 ye

51 oled Cohort Equations to Prevent HF within a primary prevention cohort derived from the electronic he

52 VD mortality) over 5 years, using a national primary prevention cohort of military veterans receiving

53 formance of the GRS appeared stronger in the primary prevention cohort with an adjusted hazard ratio

54 Conclusion In this community-based primary prevention cohort, guideline-based statin eligib

55 In the primary prevention cohort, rural residents were less lik

56 ata from intervention trials that included a primary prevention cohort.

57 ere similarly increased in the secondary and primary prevention cohorts (HR, 2.07; 95% CI, 1.43-3.00

58 were similarly reduced in the secondary and primary prevention cohorts, respectively.

59 or greater expected benefit from statins in primary prevention compared with higher-risk individuals

60 iduals benefit from long-term statin use for primary prevention depends more on the disutility associ

61 Early trials evaluating aspirin for primary prevention, done before the turn of the millenni

62 tter treatment are certainly needed for HCC, primary prevention efforts aimed at decreasing the preva

63 Primary prevention efforts are being guided by study of

64 rge, requires a redoubling of primordial and primary prevention efforts as declines in cardiovascular

65 l in low-income and middle-income countries, primary prevention efforts seeking to decrease exposure

66 table cardioverter defibrillators (ICDs) for primary prevention enrolled a limited number of women.

67 tion the net clinical benefits of aspirin in primary prevention for 3 key populations: patients with

68 le changes are the chief strategies aimed at primary prevention for many of the risk factors of cogni

69 further reductions of topsoil Pb to fulfill primary prevention for the nation's children.

70 ernment should make great efforts to provide primary prevention for those on high-risk cluster as a p

71 secondary prevention group compared with the primary prevention group (36.9 versus 15.7/1000 patient-

72 The new Primary Prevention Guideline(2) fills a critical gap by

73 onal attainment in prediction algorithms and primary prevention guidelines for CVD.

74 The role of IBD in current primary prevention guidelines is evaluated, and strategi

75 Purpose: To systematically review current primary prevention guidelines on adult cardiovascular ri

76 ege of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering lo

77 lesterol, diabetes, atrial fibrillation, and primary prevention guidelines.

78 ease, the efficacy and safety of aspirin for primary prevention has become uncertain.

79 Each has their place, but upstream primary prevention has the largest effect on reduction o

80 ersal public health system, which focuses on primary prevention, has contributed to this achievement.

81 approximately one fourth of patients with a primary prevention ICD and no previous therapy have EF >

82 Prescription fills for recipients of primary prevention ICD between 2007 and 2011 were examin

83 herapy can be predicted in ICM patients with primary prevention ICD by quantifying the LGE border zon

84 care patients with heart failure receiving a primary prevention ICD had frailty (10%) or dementia (1%

85 decision-making, is sufficient to consider a primary prevention ICD implant.

86 ta Registry ICD Registry who underwent first primary prevention ICD implantation between 2006 and 200

87 Rates of GDMT for HFrEF before primary prevention ICD implantation were low, and failur

88 is relationship between age and outcome of a primary prevention ICD in patients with nonischemic syst

89 d beta-blocker [HFBB]) within 90 days before primary prevention ICD placement in patients with HFrEF.

90 We assessed all primary prevention ICD recommendations listed in both do

91 430 women with heart failure who received a primary prevention ICD to 430 women who did not; we furt

92 educed left ventricular ejection fraction, a primary prevention ICD was associated with a significant

93 g women with heart failure with or without a primary prevention ICD.

94 European Society of Cardiology criteria for primary-prevention ICD were included.

95 has made accurate selection of patients for primary prevention ICDs a priority.

96 ty and dementia among older adults receiving primary prevention ICDs and to determine the impact of m

97 Primary prevention ICDs are efficacious at reducing all-

98 Patients with primary prevention ICDs from the National Cardiovascular

99 ve hypertrophic cardiomyopathy patients with primary prevention ICDs implanted before 2008 and follow

100 e findings support guideline-directed use of primary prevention ICDs in eligible patients.

101 Primary prevention ICDs should be considered when EF is

102 Before data collection started, primary prevention ICDs were hypothesized to reduce all-

103 To investigate the association of primary prevention ICDs with all-cause mortality in pati

104 primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic ca

105 ess likely to derive a survival benefit from primary prevention ICDs.

106 In hypertrophic cardiomyopathy, after a primary prevention implant, ICD therapy often followed p

107 ed SCD, that is, appropriate shock following primary prevention implantable cardioverter defibrillato

108 improvement in LVEF, obviating the need for primary prevention implantable cardioverter defibrillato

109 ose with DCM may not benefit from additional primary prevention implantable cardioverter-defibrillato

110 that women and black patients eligible for a primary prevention implantable cardioverter-defibrillato

111 ilated cardiomyopathy patients evaluated for primary prevention implantable cardioverter-defibrillato

112 rates occurred despite a low rate (4.0%) of primary prevention implantable cardioverter-defibrillato

113 ction fraction (HFrEF) is recommended before primary prevention implantable cardioverter-defibrillato

114 mic risk was higher among patients receiving primary prevention implantable cardioverter-defibrillato

115 The ICD indication was primary prevention in 67% and secondary in 33% patients.

116 ary prevention in 10 patients (9.6%) and for primary prevention in 94 patients (90.4%).

117 Task Force recommendations for statin use in primary prevention in a cohort of adults who experienced

118 ioverter-defibrillator (ICD) indications for primary prevention in Brugada syndrome (BrS) are still d

119 s the literature on the topic of aspirin for primary prevention in general, and in subjects with diab

120 he decision to initiate statin treatment for primary prevention in older adults requires further inve

121 all implantations and appropriate shocks for primary prevention in patients with HCM 10 to 45 years o

122 emphasis on the use of other treatments for primary prevention in patients with moderate-high future

123 However, the role of aspirin for primary prevention in patients with no overt cardiovascu

124 d questions regarding the role of aspirin in primary prevention include the optimal drug formulation,

125 Exposure to Pb has decreased through primary prevention, including removal of Pb solder from

126 ction fraction was 43 +/- 18%, and 65% had a primary prevention indication.

127 Lifetime aspirin use for primary prevention initiated at younger ages (40 to 69 y

128 t such a reduction requires a combination of primary prevention interventions and preventative effect

129 Primary prevention is a major goal, and a strategy towar

130 syndrome and 2) whether ICD implantation for primary prevention is associated with improved outcomes

131 However, aspirin as primary prevention is debated because of the risk of hem

132 Therefore, primary prevention is key to reducing social inequalitie

133 njuries is needed, and greater investment in primary prevention is needed.

134 CC/AHA guideline for expanded statin use for primary prevention is projected to treat more people, to

135 men and in younger women (in whom primordial/primary prevention may be most effective).

136 of benefits from risk-reducing therapies in primary prevention may help target therapies to those in

137 Primary prevention measures should be strengthened to pr

138 60 ml/min/1.73 m(2), in the context of both primary prevention [odds ratio (OR)/95% confidence inter

139 mmendations on initiating statin therapy for primary prevention of ASCVD (net 221 individuals appropr

140 e role of statin therapy in older adults for primary prevention of ASCVD.

141 effectiveness of hormonal contraceptives for primary prevention of asthma will be helpful to confirm

142 ance induction is an attractive approach for primary prevention of asthma.

143 s a critical step in the current approach to primary prevention of atherosclerotic cardiovascular dis

144 s accompanied by a risk assessment report on primary prevention of atherosclerotic cardiovascular dis

145 Statins are effective in the primary prevention of atherosclerotic cardiovascular dis

146 isk among populations taking statins for the primary prevention of atherosclerotic cardiovascular dis

147 ata are limited regarding statin therapy for primary prevention of atherosclerotic cardiovascular dis

148 Their role in the primary prevention of atherothrombosis remains controver

149 factors can be used to improve screening and primary prevention of atrial fibrillation, and whether b

150 corporated into clinical assessments for the primary prevention of cardiac emergencies in basketball

151 ded "initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and c

152 indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and c

153 Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outwe

154 The efficacy and safety of aspirin for primary prevention of cardiovascular disease (CVD) remai

155 long-term benefits of lowering LDL-C for the primary prevention of cardiovascular disease among indiv

156 atty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer

157 ued a guideline titled, "Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorec

158 text of previous evidence on aspirin for the primary prevention of cardiovascular disease and to appr

159 fits of aspirin, international guidelines on primary prevention of cardiovascular disease have typica

160 s and harms of behavioral counseling for the primary prevention of cardiovascular disease in adults w

161 st for screening and risk assessment for the primary prevention of cardiovascular disease in apparent

162 By contrast, the role of aspirin in primary prevention of cardiovascular disease is controve

163 Current guidelines recommend statins in the primary prevention of cardiovascular disease on the basi

164 andomised clinical trials of aspirin for the primary prevention of cardiovascular disease showed litt

165 Review, we reappraise the role of aspirin in primary prevention of cardiovascular disease, contextual

166 ive Services Task Force endorsed aspirin for primary prevention of cardiovascular disease.

167 o 75 years, who initiated statin therapy for primary prevention of cardiovascular disease.

168 whom, aspirin therapy is appropriate for the primary prevention of cardiovascular disease.

169 icle, we revisit the role of aspirin for the primary prevention of cardiovascular diseases by critica

170 discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding

171 nd patients regarding the use of aspirin for primary prevention of cardiovascular events is a suitabl

172 ll included trials evaluated aspirin for the primary prevention of cardiovascular events.

173 g from birth represents a first step towards primary prevention of childhood obesity.

174 gen and progestin has no net benefit for the primary prevention of chronic conditions for most postme

175 at estrogen alone has no net benefit for the primary prevention of chronic conditions for most postme

176 Hormone therapy for the primary prevention of chronic conditions in menopausal w

177 ds against the use of estrogen alone for the primary prevention of chronic conditions in postmenopaus

178 e of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopaus

179 he use of menopausal hormone therapy for the primary prevention of chronic conditions.

180 hough the effects of supplementation for the primary prevention of clinical cardiovascular events in

181 is identified several modifiable targets for primary prevention of colorectal cancer, including lifes

182 This paper discusses primary prevention of coronary heart disease that may be

183 amine the clinical outcomes with aspirin for primary prevention of CVD after the recent publication o

184 (1 g/d) and vitamin D(3) (2000 IU/d) in the primary prevention of CVD and cancer among 25 871 US men

185 ends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 5

186 ion to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 6

187 and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults aged 70 year

188 and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults younger than

189 /American Heart Association guideline on the primary prevention of CVD introduced the concept of risk

190 The beneficial effect of aspirin for the primary prevention of CVD is modest and occurs at doses

191 749), a randomized trial of rosuvastatin for primary prevention of CVD, component GRSs discriminate g

192 is for recommendations on use of statins for primary prevention of CVD.

193 help guide initiation of statin therapy for primary prevention of CVD.

194 ed eligibility for each of 10 major RCTs for primary prevention of CVD.

195 in whom aspirin is being considered for the primary prevention of CVD.

196 deepens the need for clinicians to focus on primary prevention of de novo humoral allosensitization.

197 e ICD therapy with conventional care for the primary prevention of death of various causes in adults

198 The decrease in disability onset due to primary prevention of diabetes could play an important p

199 ily emollient for the first year of life for primary prevention of eczema and food allergy in high-ri

200 trials of early introduction of egg for the primary prevention of egg allergy; BEAT (at 12 months, n

201 pare the efficacy of different approaches in primary prevention of esophageal variceal bleeding and o

202 Therefore, primary prevention of first stroke and secondary prevent

203 cines may reduce the economic burden through primary prevention of influenza and reduction in illness

204 Primary prevention of ischemic stroke includes lifestyle

205 Recent policies have focused on primary prevention of mental disorders in children and y

206 intervention that seems justifiable for the primary prevention of Parkinson's disease is the promoti

207 The role of nutrition in the primary prevention of peripheral artery disease (PAD), t

208 an implantable cardiac defibrillator for the primary prevention of sudden cardiac arrest after baseli

209 table cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prev

210 patients with dilated cardiomyopathy for the primary prevention of sudden cardiac death (SCD) in thos

211 implantable cardioverter defibrillators for primary prevention of sudden cardiac death are less like

212 ble cardioverter-defibrillator (ICD) use for primary prevention of sudden cardiac death in heart fail

213 table cardioverter-defibrillators (ICDs) for primary prevention of sudden death in patients with an e

214 able selection of patients likely to achieve primary prevention of sudden death with implantable defi

215 , and fatty acids, which may be important to primary prevention of T1D.

216 Previously, hormone therapy was used for the primary prevention of these chronic conditions.

217 ity is probably an effective strategy in the primary prevention of these commonly diagnosed cancers.

218 available regarding their potential role in primary prevention of type 2 diabetes.

219 ports NSBB monotherapy (0.64; 0.38-1.07) for primary prevention of variceal bleeding.

220 Data on primary prevention of zinc status and diabetes risk are

221 hma phenotypes are currently not amenable to primary prevention or early intervention because their n

222 Primary prevention participants (N=3486; 34%) were young

223 atherosclerotic cardiovascular disease in a primary prevention patient; screening for familial lipid

224 However, among primary prevention patients (n = 33,251), high polygenic

225 and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate

226 The authors then assessed whether primary prevention patients at high polygenic risk might

227 An additional 4.1% of primary prevention patients may be recommended for stati

228 ing heart disease, in a large study group of primary prevention patients with heart failure.

229 the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C <190 mg/dL with o

230 Primary prevention patients with left ventricular ejecti

231 al (Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction)

232 of cardiovascular outcomes compared with the primary prevention patients.

233 l ASCVD and in a smaller number of high-risk primary prevention patients.

234 Among the US primary prevention population represented by 3416 indivi

235 Among the 8.9% of individuals in the primary prevention population who would be recommended f

236 iovascular effects of LDL-C lowering among a primary prevention population with LDL-C >/=190 mg/dL.

237 % white; mean age = 54.7 years) composed our primary prevention population, among whom 13-28 million

238 tatins, and reflect response to therapy in a primary prevention population.

239 to cholesterol content of TRLs and sdLDL in primary prevention populations are mostly limited to cor

240 rosclerotic cardiovascular disease events in primary prevention populations with type 2 diabetes mell

241 In CVD primary prevention populations, aspirin's effect on tota

242 rdiovascular events (MACEs) in the high-risk primary prevention PREDIMED (Prevencion con Dieta Medite

243 n implantable cardioverter-defibrillator for primary prevention purposes.

244 aimed to confirm this observation in a third primary prevention randomized controlled trial.

245 Aspirin for primary prevention reduces nonfatal ischemic events but

246 lysis across the WOSCOPS, ASCOT, and JUPITER primary prevention, relative risk reduction in those at

247 The place of aspirin in primary prevention remains controversial, with North Ame

248 The role for aspirin in cardiovascular primary prevention remains controversial, with potential

249 s of risk factor modification are a focus of primary prevention research.

250 , sudden, any cardiac, or noncardiac) in the primary prevention setting.

251 Primary prevention should remain a priority for cancer c

252 k threshold considered sufficient to warrant primary prevention statin therapy, and the decision not

253 lower number of individuals recommended for primary prevention statin therapy, including many younge

254 Eligibility for primary prevention statin therapy.

255 risk individuals more likely to benefit from primary prevention statin therapy.

256 determine the difference in eligibility for primary prevention statin treatment among US adults, ass

257 These findings could have implications for primary prevention strategies and help target at-risk ad

258 d might support the development of effective primary prevention strategies for allergy and asthma in

259 injuries are nonsurvivable, only non-medical primary prevention strategies have potential to prevent

260 enting major lifestyle changes or widespread primary prevention strategies to decrease CRC risk, scre

261 Primary prevention strategies to mitigate the burden of

262 eating occasions, are potential targets for primary prevention strategies with large health impacts.

263 ul for physician-patient communication about primary prevention strategies.

264 ality and provide an opportunity for testing primary prevention strategies.

265 would contribute greatly to inform effective primary prevention strategies.

266 ear period, supporting the wider adoption of primary prevention strategies.

267 at early stages of the disease process in a primary prevention strategy.

268 ith cardiovascular disease (CVD) outcomes in primary prevention studies.

269 ested cohort within the 1995 Canadian Asthma Primary Prevention Study intervention study was performe

270 ealth Study) and CAPPS/SAGE (Canadian Asthma Primary Prevention Study/Study of Asthma, Genetics and E

271 In addition, there is evidence for use in primary prevention such as in those with diabetes mellit

272 Among 61 (37.0%) patients in primary prevention, the annual rate of appropriate ICD t

273 Despite significant progress in primary prevention, the rate of MI has not declined in y

274 k and may be useful concurrently for guiding primary prevention therapy decisions.

275 inhibitor (statin) eligibility criteria for primary prevention to include multiple risk enhancers an

276 ion or intensification of statin therapy for primary prevention to mitigate the increased risk.

277 Although vaccination is the primary prevention tool, investigations have shown low v

278 monitoring of cardiovascular risk and use of primary prevention treatment at all glucocorticoid doses

279 One large primary prevention trial found that a Mediterranean diet

280 of Scotland Coronary Prevention Study was a primary prevention trial in 45- to 64-year-old men with

281 Trial Evaluating Rosuvastatin), a randomized primary prevention trial that compared rosuvastatin trea

282 D risk factors in a multicenter, randomized, primary-prevention trial (PREDIMED-Plus) based on an int

283 events, including coronary death or MI) for primary prevention trials (1.5% lower event rate [95% CI

284 ever, in analyses of 2 randomized controlled primary prevention trials (ASCOT [Anglo-Scandinavian Car

285 Data Synthesis: Two primary prevention trials found no difference in all-cau

286 Recent primary prevention trials have also failed to consistent

287 ose that targeted communities or clinicians, primary prevention trials, and trials that reported even

288 In CVD primary prevention trials, cancer mortality (relative ri

289 e randomized clinical trials have found that primary prevention use of an implantable cardioverter-de

290 educed ejection fraction population, ICD for primary prevention was underused, although it was associ

291 of cardiovascular disease (secondary versus primary prevention) were prespecified for evaluation.

292 ss IIb assessment and is most appropriate in primary prevention when clinical decisions to initiate s

293 This goal is only fully achieved with primary prevention, which requires us to identify and pr

294 egies for the prevention of FA might include primary prevention, which seeks to prevent the onset of

295 In patients with DM without established CAD, primary prevention with aspirin is not routinely advocat

296 Consideration of the safety of primary prevention with aspirin requires an individualiz

297 cal outcomes with aspirin versus control for primary prevention with follow-up duration of >=1 year w

298 Overall, primary prevention with ICD therapy versus conventional

299 ipants from a randomized controlled trial of primary prevention with statin therapy (WOSCOPS [West of

300 Heart Association (AHA) guidelines recommend primary prevention with statins for individuals with >/=